THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, June 22, 2021
Akoya Biosciences announces that its Phenoptics solution, AstroPath, helped researchers at JHU explore and verify a first-of-its-kind biomarker signature.
FREMONT, CA: Akoya Biosciences Inc., The Spatial Biology Company, has announced that its Phenoptics solution that contributed to successfully developing a novel platform, known as AstroPath, helped researchers at Johns Hopkins University (JHU) explore and verify a first-of-its-kind biomarker signature to forecast immunotherapy response in advanced melanoma cases. The revolutionary research was published in Science on June 11 as part of ongoing cooperation between Akoya and JHU and can have applications in other types of tumors.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Immunotherapies, which use the immune system to fight cancer and improve treatment, are only effective in a small percentage of patients. Biomarkers offer the ability to identify patients who are most likely to benefit from treatment and enhance immunotherapy effectiveness. But few accurate biomarkers can accurately predict long-term results. This gap is especially significant in melanoma since no FDA-approved predictive tests exist to determine whether anti-PD-1 checkpoint inhibitors, a kind of cancer immunotherapy, would effectively treat each patient. In multi-institutional research of immuno-oncology biomarker modalities published in JAMA Oncology in 2019, spatial biomarkers surpassed gene expression profiling, tumor mutational burden (TMB) assessment, and PD-L1 immunohistochemistry (IHC) for predicting response to immunotherapy treatment.
“Researchers at The Mark Foundation Center for Advanced Genomics and Imaging at JHU and The Bloomberg-Kimmel Institute for Cancer Immunotherapy combined the Phenoptics multiplex immunofluorescence (mIF) platform with sky-mapping algorithms derived from astronomy to create AstroPath for deep whole slide imaging and spatially mapping microscopic sections of tumors. The lead investigators Dr. Janis Taube, a pathology expert, and Dr. Alexander Szalay, an astrophysicist and data science expert, are, respectively, Director of the Division of Dermopathology, and the Bloomberg Distinguished Professor in the Department of Computer Science at JHU. Akoyas Phenoptics solution, one of the underlying technologies of AstroPath, enables researchers to study how tumor and immune cells are spatially organized in a tissue sample and gives deep insights on how they interact to influence cancer progression and treatment response,” said Sneha Berry, PhD, a co-author of the paper, who is now a lead clinical research scientist at Akoya.
More in News